Better measurement of the complementarity between UK public, charity and private medical research

更好地衡量英国公共、慈善机构和私人医学研究之间的互补性

• 批准号: MR/L010801/2
• 负责人: Jonathan Grant
• 金额: $ 19.21万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FL010801%2F2
• 关键词: Better; measurement; complementarity; between; UK

Getting benefits from medical research in terms of preventing or treating illness, advancing scientific knowledge and generating economic wealth often, though not always, involves private industry. The private sector builds on and interacts with public and charity funded research and researchers; it conducts its own further research, develops and commercialises medicines and other technologies for use in health care. Theoretical and applied analyses so far published imply that public/charity funded medical research and private sector R&D are complements: extra spending on medical research stimulates extra private sector investment in R&D. But the only attempts to measure this complementarity so far have used US data and are somewhat out of date.RAND Europe and the OHE therefore propose to develop the methodology for estimating how many £s of pharmaceutical industry R&D are stimulated by an extra £ of public or charity funded medical research. We will improve on the econometric analysis used in the earlier US studies and create a UK, and up to date, dataset of public, charity and private pharmaceutical industry research spending in the UK, disaggregated into therapeutic areas.Time series data are available for total UK pharmaceutical industry R&D spending, but not broken down by therapeutic area. So we will construct estimated splits of spending by therapeutic area on the basis of two different proxies. First, we will use bibliometric analysis of peer reviewed research articles that have private sector authors based in the UK to estimate the relative weights given by the UK industry to different disease areas in its research. The necessary bibliometric database is available and permits analysis for each year from 1981 onwards. Second we will undertake a corresponding analysis of patents by therapeutic area, where that is evident, by year.To allow for likely differences between companies in their willingness to publish and their desire to patent, and given that different companies may focus on different therapeutic areas, we will explore the development of indices of companies' propensity to publish and propensity to patent. The indices will then be used to weight the publications and patents produced by those companies when using those data to proxy the split of pharmaceutical industry R&D spending.We will test the reasonableness of the proxies we develop for splitting total UK pharmaceutical industry R&D spend by therapeutic area via interviews with 12 senior company R&D managers in the UK (from the UK leading R&D companies), who will also be asked about the likelihood of, and the factors affecting, feedback from company R&D influencing public/charity research agendas.We will improve on analyses to date by separately analysing publicly funded medical research and charity funded medical research, not merely aggregating the two.We will also attempt to determine whether there is a measurable impact in the reverse direction, i.e. whether greater private pharmaceutical R&D investment stimulates greater charity or public medical research spending in similar areas.

从预防或治疗疾病、推进科学知识和创造经济财富方面的医学研究中获益，虽然并非总是如此，但私营部门往往以公共和慈善机构资助的研究和研究人员为基础并与之互动；进一步研究、开发和商业化用于医疗保健的药物和其他技术 迄今为止发表的理论和应用分析表明，公共/慈善医疗资助的研究和私营部门的研发是互补的：医学研究的额外支出刺激了私营部门对研发的额外投资。 。但迄今为止衡量这种互补性的唯一尝试是使用美国数据，并且有些过时。因此，兰德欧洲和 OHE 提议开发一种方法来估计有多少英镑的制药行业研发是由额外的公共资金刺激的。我们将改进美国早期研究中使用的计量经济学分析，并创建一个最新的英国公共、慈善和私人制药行业研究支出数据集，并按治疗领域进行分类。系列数据可用于英国制药行业的研发支出总额，但不按治疗​​领域细分，因此我们将根据两个不同的替代指标构建按治疗领域的估计支出划分，首先，我们将对私营部门的同行评审研究文章进行文献计量分析。位于英国的作者估计英国工业界在其研究中对不同疾病领域的相对权重。 必要的文献计量数据库可供使用，并允许从 1981 年开始对专利进行相应的分析。考虑到公司之间在发表意愿和申请专利的意愿方面可能存在的差异，并且鉴于不同的公司可能专注于不同的治疗领域，我们将探索公司指数的制定然后，在使用这些数据来代表制药行业研发支出的分配时，这些指数将用于对这些公司发表的出版物和专利进行加权。我们将测试我们为分配而开发的代理的合理性。英国制药业研发总额通过采访英国 12 名高级公司研发经理（来自英国领先的研发公司），了解按治疗领域划分的支出，他们还将被问及公司研发反馈影响公共/慈善研究议程的可能性和影响因素。我们将改进迄今为止的分析，分别分析公共资助的医学研究和慈善资助的医学研究，而不仅仅是将两者相加。我们还将尝试确定是否存在相反方向的可衡量的影响，即是否存在私人医药研发投资的增加会刺激类似领域慈善机构或公共医学研究支出的增加。

项目成果

Additional file 7: of Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom

附加文件 7：量化政府和慈善机构资助医学研究对英国私人研发资助的经济影响

• DOI: http://dx.10.6084/m9.figshare.c.3601037_d7
• 发表时间: 2016
• 作者: Sussex J

Additional file 4: of Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom

附加文件 4：量化政府和慈善机构资助医学研究对英国私人研发资助的经济影响

• DOI: http://dx.10.6084/m9.figshare.c.3601037_d3
• 发表时间: 2016
• 作者: Sussex J

Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom.

量化政府和慈善机构资助医学研究对英国私人研究和开发资金的经济影响。

• DOI: http://dx.10.1186/s12916-016-0564-z
• 发表时间: 2016
• 期刊: BMC medicine
• 影响因子: 9.3
• 作者: Sussex J

Additional file 8: of Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom

附加文件 8：量化政府和慈善机构资助医学研究对英国私人研发资助的经济影响

• DOI: http://dx.10.6084/m9.figshare.c.3601037_d1
• 发表时间: 2016
• 作者: Sussex J

Additional file 5: of Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom

附加文件 5：量化政府和慈善机构资助医学研究对英国私人研发资助的经济影响

• DOI: http://dx.10.6084/m9.figshare.c.3601037_d5
• 发表时间: 2016
• 作者: Sussex J